| P2093 | author name string | Bo Zhang | |
| | Keijiro Saku | |
| | Satoshi Imaizumi | |
| | Shin-Ichiro Miura | |
| | Kohei Takata | |
| P2860 | cites work | Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association | Q22306356 |
| | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 |
| | Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis | Q24634165 |
| | Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies | Q24658205 |
| | Review of clinical practice guidelines for the management of LDL-related risk | Q26859189 |
| | Insulin resistance, hyperglycemia, and atherosclerosis | Q27011696 |
| | Concept of vulnerable/unstable plaque | Q27687028 |
| | Biochemistry and molecular cell biology of diabetic complications | Q28131781 |
| | Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial | Q28181984 |
| | Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry | Q28194991 |
| | Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study | Q28211493 |
| | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 |
| | 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q28301815 |
| | Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES) | Q28373163 |
| | Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis | Q28482437 |
| | Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence | Q28572590 |
| | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 |
| | Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins | Q29547534 |
| | Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 |
| | Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 |
| | Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris | Q78772850 |
| | Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome | Q79165981 |
| | Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: an intravascular ultrasound study | Q80175778 |
| | The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells | Q81161461 |
| | Angiotensin II enhances thrombosis development in renovascular hypertensive rats | Q81873133 |
| | Effect of two intensive statin regimens on progression of coronary disease | Q82513300 |
| | Pathology of the vulnerable plaque | Q83187650 |
| | Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS | Q83461319 |
| | Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques | Q84105610 |
| | A reconstituted high density lipoprotein containing the V156E mutant of apolipoprotein A-I exhibits anti-atherosclerotic activity in Apo-E deficient mice | Q84307173 |
| | Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure--are they important for doctors? | Q84800933 |
| | Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall | Q85054596 |
| | Impact of cigarette smoking cessation on high-density lipoprotein functionality | Q85800262 |
| | Evaluation of serial changes in tissue characteristics during statin-induced plaque regression using virtual histology-intravascular ultrasound studies | Q86121117 |
| | Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis | Q86150625 |
| | Circulating Th17 and Th1 cells expressing CD161 are associated with disease activity in rheumatoid arthritis | Q87040336 |
| | Hemoglobin A(1c) in nondiabetic patients: an independent predictor of coronary artery disease and its severity | Q88220020 |
| | IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis | Q36849075 |
| | FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice | Q36974226 |
| | Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo | Q37151837 |
| | Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis | Q37209541 |
| | Pleiotropic effects of statins. - Basic research and clinical perspectives -. | Q37252114 |
| | The role of adaptive T cell immunity in atherosclerosis | Q37339539 |
| | Correlation of severity of coronary artery disease with insulin resistance. | Q37348197 |
| | Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarction | Q37374628 |
| | Lipid effects of smoking | Q68253165 |
| | Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice | Q69741608 |
| | In vivo coronary angioscopy | Q71688966 |
| | Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators | Q72998299 |
| | Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus | Q73134572 |
| | Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine | Q73565510 |
| | Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine | Q74596197 |
| | Relationship between coronary artery remodeling and plaque vulnerability | Q77690022 |
| | The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 |
| | Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy | Q29616232 |
| | Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study | Q29617822 |
| | CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 |
| | Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 |
| | Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 |
| | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 |
| | Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | Q29622926 |
| | Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. | Q30385604 |
| | Association of insulin resistance and coronary artery remodeling: an intravascular ultrasound study | Q30408893 |
| | Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603. | Q31835249 |
| | Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria | Q31931889 |
| | Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits | Q31956644 |
| | The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis | Q33193289 |
| | TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression | Q33338215 |
| | Inflammation in atherosclerosis: from pathophysiology to practice | Q33709505 |
| | Pathology of the coronary arteries in smokers and non-smokers | Q33759329 |
| | Long-term effects of intensive glucose lowering on cardiovascular outcomes | Q33851861 |
| | Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations | Q33854955 |
| | Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions | Q33916802 |
| | Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration | Q33929187 |
| | Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials | Q34083400 |
| | High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport | Q34123188 |
| | Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. | Q34150800 |
| | Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk | Q34155924 |
| | Effects of dalcetrapib in patients with a recent acute coronary syndrome | Q34309967 |
| | Type 1 diabetes: new perspectives on disease pathogenesis and treatment | Q34321603 |
| | Cigarette suppresses the expression of P4Halpha and vascular collagen production | Q34348594 |
| | The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes | Q34389287 |
| | T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein | Q34390132 |
| | Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors | Q34432988 |
| | Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis | Q34462095 |
| | Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes | Q34479098 |
| | Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease | Q34491319 |
| | Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial | Q34501729 |
| | Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis | Q34537191 |
| | Inhibition of the renin-angiotensin system and target organ protection | Q37406883 |
| | Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states | Q37617131 |
| | Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature | Q37728075 |
| | Intensive glycemic control and cardiovascular disease: an update | Q37734216 |
| | Pathophysiology of acute coronary syndrome assessed by optical coherence tomography | Q37765738 |
| | IL-17A Is Proatherogenic in High-Fat Diet-Induced and Chlamydia pneumoniae Infection-Accelerated Atherosclerosis in Mice | Q37852203 |
| | Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. | Q37992757 |
| | Regulatory T cells in atherogenesis. | Q38002291 |
| | Thiazolidinediones and PPARγ agonists: time for a reassessment | Q38003533 |
| | Thiazolidinedione safety | Q38012205 |
| | Mechanisms of coronary thrombosis in cigarette smoke exposure | Q38107776 |
| | Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins | Q38194736 |
| | Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial | Q38398332 |
| | C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy | Q38444421 |
| | Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials | Q38499877 |
| | The paradoxical role of IL-17 in atherosclerosis | Q38528593 |
| | Effect of Smoking on Metalloproteinases (MMPs) Activity in Patients with Acute Myocardial Infarction (AMI). | Q38587974 |
| | High-density lipoprotein--the clinical implications of recent studies | Q38700033 |
| | The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study | Q39433797 |
| | Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice | Q39446360 |
| | An overview of the quantitative influence of several risk factors on progression of atherosclerosis in young people in the United States. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group | Q40383857 |
| | New insights into the pathogenesis of atherosclerosis as revealed by PDAY. Pathobiological Determinants of Atherosclerosis in Youth | Q40557370 |
| | Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection | Q40630962 |
| | Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death | Q40993289 |
| | Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection | Q41057180 |
| | A prospective natural-history study of coronary atherosclerosis | Q41983924 |
| | Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase | Q42075557 |
| | Proinflammatory and prothrombotic effects of hypoglycemia | Q42745265 |
| | Detection of vulnerable coronary plaques by color fluorescent angioscopy | Q43098195 |
| | Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial | Q43142931 |
| | Impact of glucose fluctuation and monocyte subsets on coronary plaque rupture | Q43428360 |
| | Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris | Q43484455 |
| | Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. | Q43507476 |
| | A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. | Q43567153 |
| | Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial | Q43606926 |
| | High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization | Q43653251 |
| | Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice | Q43909351 |
| | Inhibition of intestinal cholesterol absorption by ezetimibe in humans | Q44172138 |
| | Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia | Q44243290 |
| | Influences of Increased Oxidative Stress on Endothelial Function, Platelets Function, and Fibrinolysis in Hypertension Associated with Glucose Intolerance | Q44431608 |
| | Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial | Q44459441 |
| | Plaque-stabilizing effect of angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker in a rabbit plaque model | Q44522078 |
| | Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus | Q44525848 |
| | Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). | Q34539439 |
| | Advanced glycation end products: sparking the development of diabetic vascular injury | Q34555042 |
| | Diabetes and atherosclerosis: epidemiology, pathophysiology, and management | Q34646074 |
| | Update on acute coronary syndromes: the pathologists' view | Q34646452 |
| | HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events | Q34693837 |
| | CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells | Q34709777 |
| | Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 |
| | Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis | Q34779550 |
| | Healthy lifestyle in the primordial prevention of cardiovascular disease among young women | Q34925012 |
| | Decreased naive and increased memory CD4(+) T cells are associated with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis | Q34979474 |
| | HDL cholesterol efflux capacity and incident cardiovascular events | Q35021594 |
| | Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice | Q35050827 |
| | Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis | Q35114963 |
| | Is atherosclerosis an autoimmune disease? | Q35123740 |
| | Role of oxidative stress in endothelial insulin resistance. | Q35179243 |
| | High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function | Q35562936 |
| | Autoimmune and inflammatory mechanisms in atherosclerosis | Q35698466 |
| | Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging | Q35722414 |
| | Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography | Q35782024 |
| | The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice | Q35792034 |
| | Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production | Q35845445 |
| | The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment | Q35915712 |
| | Mechanisms of suppression by suppressor T cells | Q36078047 |
| | Protective effect of the inhibition of the renin-angiotensin system on aging | Q36101343 |
| | Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol | Q36242351 |
| | Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people | Q36334667 |
| | Smoking, metalloproteinases, and vascular disease | Q36336918 |
| | Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype | Q36379539 |
| | Role of angiotensin II receptor blockers in atherosclerotic plaque stability. | Q36382568 |
| | Inflammation and cellular immune responses in abdominal aortic aneurysms | Q36404719 |
| | T cells in atherogenesis: for better or for worse? | Q36594608 |
| | Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. | Q36756284 |
| | Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions | Q36821404 |
| | Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy | Q44558732 |
| | Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies | Q44698439 |
| | Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial | Q44783935 |
| | The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. | Q44812728 |
| | High-density lipoprotein cholesterol level is associated with fibrous cap thickness in acute coronary syndrome | Q44900816 |
| | Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia | Q44933941 |
| | Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe | Q45412615 |
| | Influence of high-dose lipid lowering treatment compared to low-dose lipid lowering treatment on plaque composition assessed by intravascular ultrasound virtual histology in patients with ST-segment elevation acute myocardial infarction: the VIRHIST | Q45767227 |
| | Metformin for cardiovascular disease: promise still unproven | Q45875709 |
| | Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. | Q45921724 |
| | Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells | Q46043854 |
| | Glucose "peak" and glucose "spike": Impact on endothelial function and oxidative stress | Q46297347 |
| | Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes | Q46401219 |
| | Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma | Q46413344 |
| | Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study | Q46524848 |
| | Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes | Q46553111 |
| | The Th17/Treg imbalance in patients with acute coronary syndrome | Q46737661 |
| | Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy | Q46754027 |
| | Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano | Q47347235 |
| | Increased Th1 activity in patients with coronary artery disease | Q47624706 |
| | The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group | Q47690865 |
| | Plasma interleukin-10 levels and adverse outcomes in acute coronary syndrome. | Q48823158 |
| | Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. | Q50882502 |
| | Blood glucose and coronary artery disease in nondiabetic patients. | Q51499028 |
| | Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. | Q51500191 |
| | Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. | Q51562831 |
| | Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. | Q51631986 |
| | CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. | Q51750588 |
| | Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. | Q51767750 |
| | USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION. | Q53040470 |
| | Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. | Q53180650 |
| | Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. | Q53238861 |
| | Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. | Q53359026 |
| | Impact of statins on serial coronary calcification during atheroma progression and regression. | Q53560051 |
| | T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: statins as immunomodulatory agents? | Q53584951 |
| | Role of coronary risk factors in blood thrombogenicity and acute coronary syndromes | Q53853760 |
| | Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. | Q54449577 |
| | Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. | Q54585173 |
| | Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. | Q55034145 |
| | Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study | Q57571736 |
| | Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis | Q57740244 |
| | Glycemic variability predicts cardiovascular complications in acute myocardial infarction patients with type 2 diabetes mellitus | Q57916593 |
| | Molecular Fingerprint of Interferon-γ Signaling in Unstable Angina | Q58230292 |
| | Perturbation of the T-Cell Repertoire in Patients With Unstable Angina | Q58230319 |
| | Stabilisation of atherosclerotic plaques | Q59260971 |
| | Association Between IVUS Findings and Adverse Outcomes in Patients With Coronary Artery Disease | Q63915333 |
| | Diabetes and cardiovascular risk factors: the Framingham study | Q67462912 |
| | Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group | Q67722527 |
| | Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study | Q67948444 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 304-21 | |
| P577 | publication date | 2016-08-01 | |
| P1433 | published in | Cardiovascular diagnosis and therapy | Q26842243 |
| P1476 | title | Stabilization of high-risk plaques | |
| P478 | volume | 6 | |